Genus plc reported a 35% rise in adjusted pre-tax profit for its 2026 financial year, launched a further £60m share buyback and continued to win regulatory approvals for its gene-edited pig.

Genus plc (LSE:GNS), the animal genetics specialist behind the PIC pig breeding and ABS bovine businesses, has given investors plenty to consider in recent weeks. Its preliminary results for the year ended 30 June 2026, released on 10 September, showed sharply higher profits, a much healthier balance sheet following the partial sale of its Chinese pig operations, and a fresh commitment to return cash to shareholders. The FTSE 250 company's shares were trading at around 2,370p in mid-October, valuing the group at roughly £1.5bn.

Profit growth despite lower revenue

Revenue slipped 2% to £658.1m, but adjusted pre-tax profit increased 35% to £100.2m, or 30% at constant currency. Adjusted basic earnings per share rose by the same proportion to 110.3p. Statutory pre-tax profit jumped to £310.5m, boosted by a gain of about £204m on the disposal of a 51% stake in PIC China.

PIC delivered adjusted operating profit, including joint ventures, of £130.8m, up 17%, on volume growth of 12%. ABS, the dairy and beef genetics arm, lifted adjusted operating profit by 17% to £22.9m, helped by savings from its Value Acceleration Programme, even though its revenue fell 3%.

Net debt fell to £71.8m from £228.2m a year earlier, taking leverage down to about 0.4 times. That gave the board room to propose a final dividend of 24.0p, taking the full-year payout to 35.2p, up 10%, and to announce an additional £60m share buyback expected to be completed during the 2027 financial year.

Gene-edited pig and outlook

A central part of the Genus (LSE:GNS) investment case is its PRRS-resistant pig, which has been gene-edited to resist one of the most costly diseases in global pork production. During the year the company secured approvals or favourable regulatory determinations in Argentina, Canada, Uruguay and Peru, and said commercialisation is starting in selected Latin American markets. It continues to pursue approvals in further jurisdictions, including Mexico, Japan and China, which are important for export-oriented pork producers. Progress on these remaining markets is widely seen as a key determinant of the pace at which the trait can be rolled out commercially.

Chief executive Jorgen Kokke described the year as a solid performance. For the 2027 financial year, Genus expects adjusted pre-tax profit at constant currency to be in line with market consensus, which the company put at an average of £93.0m within a range of £87.0m to £96.6m. That would be moderately above normalised 2026 profit of £90.3m, which strips out contributions no longer consolidated following the China transaction. The company said profits are expected to be weighted towards the second half.

Investors will be watching for updates on regulatory timelines for the gene-edited pig, the health of global pork producer margins and progress on the ABS turnaround. The company's next trading statement, expected around its annual general meeting later in the autumn, may offer the next read on current trading.

Balancing growth and returns

The results also highlight how the China transaction has reshaped the group's finances. By selling a majority stake in PIC China while retaining a significant interest, Genus has reduced its exposure to a volatile pork market, crystallised value and cut borrowing. The lower debt position allows the company to fund continued investment in R&D, including its gene-editing programme, while also increasing distributions to shareholders through both dividends and buybacks. Management has indicated that disciplined capital allocation will remain a priority as the commercial roll-out of the PRRS-resistant trait gathers pace.